menu

Treating IBS-D as a Multi-Symptom Condition

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Treating IBS-D as a Multi-Symptom Condition

Program Information
Recommended

Program Information

Healthcare Image
RestartResume

When treating irritable bowel syndrome with diarrhea, it’s important to be cognizant of symptoms beyond just abdominal pain and diarrhea.

Please see

Indication and Important Safety Information below.

  • Overview

    Based on the Rome IV criteria, the diagnosis of irritable bowel syndrome with diarrhea (IBS-D) is made by the presence of abdominal pain associated with a change in stool frequency and/or form over a set period of time, along with the exclusion of alarm features and limited diagnostic testing. The diagnostic criteria are important, and it is also important to understand the other symptoms that may accompany IBS-D. That’s why Dr. Darren Brenner is here to share how we can recognize and treat IBS-D as a multi-symptom condition and learn about treatment options like XIFAXAN, an FDA-approved treatment for adults with IBS-D.

    © 2021 Salix Pharmaceuticals or its affiliates. XIFI.0149.USA.21

  • Indication

    XIFAXAN® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

  • Important Safety Information (ISI)

    • XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema, and anaphylaxis.
    • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
    • There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment. Caution should be exercised when administering XIFAXAN to these patients.
    • Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed. Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs, significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin.
    • In clinical studies, the most common adverse reactions for XIFAXAN in IBS-D (≥2%) were nausea (3%) and ALT increased (2%).
    • INR changes have been reported in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be required.
    • XIFAXAN may cause fetal harm. Advise pregnant women of the potential risk to a fetus.

    To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    Please click here for full Prescribing Information.

Schedule22 May 2022
Webpack App